Loading...

Cronos Group Inc.

CRONNASDAQ
Healthcare
Drug Manufacturers - Specialty & Generic
$2.05
$-0.02(-0.97%)

Cronos Group Inc. (CRON) Stock Overview

Explore Cronos Group Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B+

Score: 71.4/100

Key Financials

Market Cap790.1M
P/E Ratio15.84
EPS (TTM)$0.14
ROE0.05%
Fundamental Analysis

AI Price Forecasts

1 Week$1.85
1 Month$1.69
3 Months$1.92
1 Year Target$1.67

CRON Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Cronos Group Inc. (CRON) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 54.36, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $1.67.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 15.84 and a market capitalization of 790.1M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Frequently Asked Questions

;